Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients

Inclusion Criteria: 1. Written informed consent must be obtained before any assessment is performed. 2. No previous treatment for Hepatitis C (HCV) infection (i.e. HCV treatment-naïve) 3. Chronic hepatitis C (G2 or G3) virus infection diagnosed Exclusion criteria: 1. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of that medication before enrollment. 2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes 3. Hepatitis B Surface Antigen (HBsAg) positive 4. Human immunodeficiency virus (HIV) positive. \-